logo

  • The Company
    The Company
      • Promore Pharma in Brief
      • Vision and Strategy
      • Market
      • Team
      • Board of Directors
  • Projects
    Projects
      • Project Overview
      • PXL01 – Prevention of Post-Surgical Adhesions and Scars
      • LL-37 – Healing of Chronic Wounds
      • Publications
  • Investors
    Investors
      • Promore Pharma on Nasdaq First North Growth Market
        • Certified Adviser
      • The Share
        • Shareholders
        • Warrant Programs
        • Share capital development
      • Financial Reports
      • Press Releases
      • Prospectuses
      • Presentations and Events
      • Calendar
      • Subscribe
  • Corporate Governance
    Corporate Governance
      • Corporate Governance
      • General Meeting
        • General Meetings
      • Nomination Committee
        • Nomination Committees
      • The Board of Directors
        • Board of Directors
      • The Management
        • Management
      • Remunerations and Remuneration Committee
      • Auditor and Audit Committee
      • Articles of Association
      • Certificate of Registration
  • Media
    Media
      • Press Releases
      • Imagebank
      • Subscribe
  • Contact
    Contact
      • Office
      • Investors
      • Media
Svenska
The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • PXL01 – Prevention of Post-Surgical Adhesions and Scars
  • LL-37 – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
    • Certified Adviser
  • The Share
    • Shareholders
    • Warrant Programs
    • Share capital development
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
    • General Meetings
  • Nomination Committee
    • Nomination Committees
  • The Board of Directors
    • Board of Directors
  • The Management
    • Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Investors

  • Promore Pharma on Nasdaq First North Growth Market
    • Certified Adviser
  • The Share
    • Shareholders
    • Warrant Programs
    • Share capital development
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe

Contact

Jenni Björnulfson

 Chief Financial Officer (CFO) +46 708 55 38 05

Financial Reports

All years
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
Select category
  • Annual Reports
  • Interim Reports
May 26, 2020

Promore Pharma AB (publ) Interim report January – March 2020

May 5, 2020

Promore Pharma’s Annual Report 2019 Published

February 18, 2020

Promore Pharma AB (publ) Year-end report 2019

November 22, 2019

Promore Pharma AB (publ) Interim report January – September 2019

August 28, 2019

Promore Pharma AB (publ) Interim report January – June 2019

May 21, 2019

Promore Pharma AB (publ) Interim report January – March 2019

April 30, 2019

Promore Pharma 2018 Annual report published

November 23, 2018

Promore Pharma AB (publ) Interim report January – September 2018

August 20, 2018

Interim report January – June 2018

May 16, 2018

Promore Pharma AB (publ) Interim report January – March 2018

April 25, 2018

Promore Pharma 2017 Annual report published

February 6, 2018

Year-end report 2017

November 21, 2017

Interim report January – September 2017

August 30, 2017

Interim report January – June 2017

May 19, 2017

Interim report January – March 2017

May 17, 2017

Promore Pharma AB – Annual Report July 2015 – December 2016

April 25, 2017

Pergamum AB – Annual Report July 2015 – December 2016

January 29, 2016

Pergamum AB – Annual Report 2014-07-01–2015-06-30

December 17, 2015

Lipopeptide AB – Annual Report 2014-07-01–2015-06-30

The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • PXL01 – Prevention of Post-Surgical Adhesions and Scars
  • LL-37 – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
  • The Share
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
  • Nomination Committee
  • The Board of Directors
  • The Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Promore Pharma AB. Address: Fogdevreten 2, SE-171 65 Solna, Sweden. Phone: +46 8 124 548 59. E-mail: info@promorepharma.com. Registration number: 556639-6809.

  • Personal data
  • About cookies

Welcome to Promore Pharma AB’s website. In order to optimize your use of our website we use cookies. A cookie is a text file stored on your computer. If you want more information about what a cookie is, what the purpose of the cookie is and how you can block or delete cookies, please read the our cookie guidelines “About cookies”. By continuing, you agree to our use of cookies.

Yes, I accept